Machado C M, Cardoso M R A, da Rocha I F, Boas L S V, Dulley F L, Pannuti C S
Virology Laboratory (LIM 52-HCFMUSP) of Instituto de Medicina Tropical de São Paulo, São Paulo, Brazil.
Bone Marrow Transplant. 2005 Nov;36(10):897-900. doi: 10.1038/sj.bmt.1705159.
Influenza vaccine is recommended yearly for recipients after the sixth month of BMT. Although a higher risk of complications of influenza is expected to occur in BMT patients, no study has addressed the clinical efficacy of influenza vaccination in this setting. Focusing on the clinical benefits of influenza vaccination, we evaluated the risk factors for influenza infection in a cohort of 177 BMT recipients followed up for 1 year. Influenza was diagnosed in 39 patients. Multivariate analyses showed that seasonal exposure and more aggressive conditioning regimens were independently associated with increased risk for influenza. Influenza vaccination and steroid use showed a protective role. Of the 43 patients who had received BMT longer than 6 months, 19 were vaccinated (compliance rate = 44.2%) and vaccine efficacy was 80%. We conclude that influenza vaccination plays an important role in protecting BMT recipients against influenza and all efforts should be made to ensure good compliance with vaccination.
建议异基因造血干细胞移植（BMT）术后六个月以上的受者每年接种流感疫苗。尽管预计BMT患者发生流感并发症的风险较高，但尚无研究探讨流感疫苗接种在此情况下的临床疗效。基于流感疫苗接种的临床益处，我们评估了177名接受BMT并随访1年的受者感染流感的风险因素。39名患者被诊断为流感。多因素分析显示，季节性暴露和更强化的预处理方案与流感风险增加独立相关。流感疫苗接种和使用类固醇显示出保护作用。在43名接受BMT超过6个月的患者中，19名接种了疫苗（依从率 = 44.2%），疫苗效力为80%。我们得出结论，流感疫苗接种在保护BMT受者免受流感感染方面发挥着重要作用，应尽一切努力确保良好的疫苗接种依从性。
